HEALTHCARE RESOURCE UTILIZATION AND COSTS BY CARDIOVASCULAR RISK LEVEL: RESULTS FROM THE LATINO STUDY



M Afonso-Silva¹, C Gavina^{2,3}, D Seabra Carvalho^{2,4}, F Araújo⁵, D Grangeia⁶, T Taveira-Gomes^{4,7,8,9,10,11}

¹ HE&OR / RWE, Novartis Farma, Produtos Farmacêuticos SA, Porto Salvo, Portugal; ² Cardiology Department, Pedro Hispano Hospital, Matosinhos, Portugal; ³ Department of Medicine, Faculty of Medicine of University of Porto; ⁴ Department of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, Porto, Portugal; ⁵ Hospital Lusíadas, Lisboa, Portugal; ⁶ Medical department, Novartis Farma, Produtos Farmacêuticos SA, Porto Salvo, Portugal; ⁷ MTG Research and Development Lab, Porto, Portugal; ⁸ TOXRUN – Toxicology Research Unit, University Institute of Health Sciences, Advanced Polytechnic and University Cooperative (CESPU), CRL, Gandra, Portugal; ⁹ UCIBIO-REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal; ¹⁰ Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; ¹¹ Faculty of Health Sciences, University Fernando Pessoa (FCS-UFP), Porto, Portugal.


BACKGROUND/OBJECTIVES

- Cardiovascular diseases (CVD) are the main cause of mortality in Portugal, with stroke and ischemic heart disease as the leading causes of death among CVD (1,2).
- Atherosclerosis entails a high burden and costs in the Portuguese population, accounting for 260,943 disability-adjusted life years and 11% of all health expenditures in 2016 (3,4).
- This analysis aimed to assess cardiovascular (CV) related healthcare resource utilization (HRU) and respective costs by CV risk level in patients followed at a Portuguese local health unit.

METHODS

- Multicenter cohort study (LATINO) using data from a local health unit (Unidade Local de Saúde de Matosinhos [ULSM]) composed by 14 primary care centers and one central hospital.
 - ULSM represents ~90% of the adult population of the geographic region of Matosinhos (the eight most inhabited municipality in the country and the fourth in the northern region) (5).
- Patients aged 40-80 years-old, alive at 31/12/2019 (index date), and with ≥1 general practitioner (GP) appointment in the 3 years prior to index date were included.
- Data sources used were all electronic health records available since health unit inception (2000-2019), including ICD-9/ICD-10 and ICPC-2 data, laboratory exams, clinical measurements, medication, family structure and echocardiography.
- HRU analyzed included CV-related lifetime hospital episodes (hospitalizations, outpatient visits, and emergency room [ER] visits) and GP appointments.
 - CV-related was defined as any episode with an ICD-10 diagnosis under the I chapter on any position, or matched ICD-9 codes.
- Median length-of-stay per patient was also assessed.
- Lifetime costs (2000-2019) were calculated based on the reference cost for each episode (excluding therapy and test and diagnostic procedures costs).
- CV risk categories (low, intermediate, high and very-high risk) were defined and fully implemented according to the 2019 ESC/EAS Guidelines (except imaging, surgical procedures and biomarkers not used in routine practice) (**Figure 1**) (6).

Figure 1. Cardiovascular risk categories defined as per 2019 ESC/EAS guidelines (6)




RESULTS

 A total of 81,731 patients (31% low, 28% intermediate, 21% high and 16% very high CV risk) corresponding to 5M lifetime episodes (24%, 27%, 24% and 25% in each CV risk category, respectively) were analyzed.

RESULTS (cont.)

- Very high-risk patients were responsible for 43% of the CV-related lifetime hospitalizations, 47% of ER visits, 31% of outpatient visits and 24% of GP visits (**Figure 2**).
- Whereas high-risk patients were responsible for 22%, 17%, 20% and 25% of the CV-related lifetime hospitalizations, ER, outpatient and GP visits, respectively (**Figure 2**).


Figure 2. Distribution of HRU among all cardiovascular risk categories



GP, general practitioner; HRU, healthcare resource utilization.

- Very high-risk patients were accounted for 52% of all CV-related hospitalization days.
- The median length-of-stay per patient almost doubles in very high-risk patients versus the other CV risk categories (**Figure 3**).

Figure 3. Median length-of-stay per patient in CV-related hospitalizations in each cardiovascular risk category



- Despite being 37% of the total population, very high and high-risk patients represented 65% of total costs.
- The lifetime CV-related cost was 4,281€ per very high-risk patient and 1,699€ per high-risk.

CONCLUSIONS

- There is a steep healthcare resource utilization in the highest CV risk patients.
- These data may help inform the development of impact assessment strategies to optimize disease management in the highest CV risk patients, reducing HRU and respective economic burden.

REFERENCES

1. Statistics Portugal [Instituto Nacional de Estatística]. Causes of Death 2017 [Causas de Morte: 2017]. Lisboa: INE, 2019; 2. DGS Programa nacional para as doenças cérebro-cardiovasculares. 2017. Ministério da Saúde. Retrato da Saúde, Portugal. 2018; 3. Costa J, et al. The burden of atherosclerosis in Portugal. European Heart Journal — Quality of Care and Clinical Outcomes. 2020;0:1-9; 4. Costa J, Alarcão J, Amaral-Silva A, et al. Os custos da aterosclerose em Portugal. Rev Port Cardiol. 2021. 5. Portuguese Census 2021. 6. Mach et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020; 41(1):111–188.